GSK India announced a substantial increase in its consolidated profit for the third quarter, reaching 2.18 billion rupees ($26.18 million), up from last year's 1.93 billion rupees. The announcement was made on Thursday, and the surge in profits was mainly driven by robust growth in general medicine and vaccine sales.
General medicine sales saw a 5% increase, while vaccine sales experienced a remarkable 10% upsurge, with Shingrix leading the charge. The company's operational revenue also rose by 4.4%, reaching 9.57 billion rupees.
In addition to the growth in sales, GSK India also reported a notable cost reduction of 31.2% in materials, further contributing to their increased profits.
Bhushan Akshika, GSK's Managing Director, highlighted the company's strong position in key therapy areas, particularly anti-infectives and dermatology. This strong performance underscores GSK India's ongoing commitment to delivering high-quality healthcare solutions and its ability to adapt to market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.